GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » Total Liabilities

Predictive Oncology (FRA:S1K) Total Liabilities : €6.02 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology Total Liabilities?

Predictive Oncology's Total Liabilities for the quarter that ended in Mar. 2024 was €6.02 Mil.

Predictive Oncology's quarterly Total Liabilities declined from Sep. 2023 (€6.11 Mil) to Dec. 2023 (€5.64 Mil) but then increased from Dec. 2023 (€5.64 Mil) to Mar. 2024 (€6.02 Mil).

Predictive Oncology's annual Total Liabilities increased from Dec. 2021 (€3.10 Mil) to Dec. 2022 (€3.75 Mil) and increased from Dec. 2022 (€3.75 Mil) to Dec. 2023 (€5.64 Mil).


Predictive Oncology Total Liabilities Historical Data

The historical data trend for Predictive Oncology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Total Liabilities Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.03 8.56 3.10 3.75 5.64

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.08 5.78 6.11 5.64 6.02

Predictive Oncology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Predictive Oncology's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.623+(2.007+0.0049999999999994
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.64

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=13.22-7.585
=5.64

Predictive Oncology's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.156+(1.865+0.0030000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=6.02

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=9.753-3.73
=6.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Predictive Oncology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (FRA:S1K) Business Description

Traded in Other Exchanges
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines